Sign Out
The recommended dose is 100 mg administered by intravenous infusion every 12 weeks. Some patients may benefit from a dosage of 300 mg administered by intravenous infusion every 12 weeks.
Elderly patients (>65 years): Although patients up to 75 years of age were included in one study, the Vyepti clinical study program did not include numbers of patients aged ≥65 to determine whether they responded differently than younger patients. Pharmacokinetics of Vyepti is not affected by age.
Use in Pediatrics: Safety and efficacy of eptinezumab in pediatric patients under 18 yr has not been established.
Route of Administration: Eptinezumab is for intravenous use only after dilution.
